TY - JOUR
T1 - MHC class II ubiquitination regulates dendritic cell function and immunity
AU - Wilson, Kayla R.
AU - Jenika, Devi
AU - Blum, Annabelle B.
AU - Macri, Christophe
AU - Xu, Bangyan
AU - Liu, Haiyin
AU - Schriek, Patrick
AU - Schienstock, Dominik
AU - Francis, Lauren
AU - Makota, F. Victor
AU - Ishido, Satoshi
AU - Mueller, Scott N.
AU - Lahoud, Mireille H.
AU - Caminschi, Irina
AU - Edgington-Mitchell, Laura E.
AU - Villadangos, Jose A.
AU - Mintern, Justine D.
N1 - Funding Information:
This work was supported by Department of Health Australia, National Health and Medical Research Council grants or fellowships 1058193, 1113293, 1154502, and 1163090 (to J.A.V.) and 1161101 and 1129672 (to J.D.M.), Department of Education
Funding Information:
and Training, Australian Research Council (ARC) grants or fellowships 160103134, 170102471, and 190102213 to J.A.V. and 190101242, 180100844, 160101373, and 180100521 (to J.D.M.), a Human Frontiers Science Program grant (0064/2011 to J.A.V.), and the Australian Government’s National Health and Medical Research Council Victorian State Government Operational Infrastructure Support and the Independent Research Institutes Infrastructure Support Scheme. L.E.E.-M. was supported by the Russell and Mab Grimwade Miegunyah Fund, funded at the University of Melbourne, which supplied a Grimwade Fellowship, and an ARC Discovery Early Career Researcher Award Fellowship (ARC, DE180100418).
Funding Information:
This work was supported by Department of Health Australia, National Health and Medical Research Council grants or fellowships 1058193, 1113293, 1154502, and 1163090 (to J.A.V.) and 1161101 and 1129672 (to J.D.M.), Department of Education and Training, Australian Research Council (ARC) grants or fellowships 160103134, 170102471, and 190102213 to J.A.V. and 190101242, 180100844, 160101373, and 180100521 (to J.D.M.), a Human Frontiers Science Program grant (0064/2011 to J.A.V.), and the Australian Government?s National Health and Medical Research Council Victorian State Government Operational Infrastructure Support and the Independent Research Institutes Infrastructure Support Scheme. L.E.E.-M. was supported by the Russell and Mab Grimwade Miegunyah Fund, funded at the University of Melbourne, which supplied a Grimwade Fellowship, and an ARC Discovery Early Career Researcher Award Fellowship (ARC, DE180100418).
Publisher Copyright:
Copyright © 2021 by The American Association of Immunologists, Inc. All rights reserved.
PY - 2021/11/1
Y1 - 2021/11/1
N2 - MHC class II (MHC II) Ag presentation by dendritic cells (DCs) is critical for CD4+ T cell immunity. Cell surface levels of MHC II loaded with peptide is controlled by ubiquitination. In this study, we have examined how MHC II ubiquitination impacts immunity using MHC IIKRKI/KI mice expressing mutant MHC II molecules that are unable to be ubiquitinated. Numbers of conventional DC (cDC) 1, cDC2 and plasmacytoid DCs were significantly reduced in MHC IIKRKI/KI spleen, with the remaining MHC IIKRKI/KI DCs expressing an altered surface phenotype. Whereas Ag uptake, endosomal pH, and cathepsin protease activity were unaltered, MHC IIKRKI/KI cDC1 produced increased inflammatory cytokines and possessed defects in Ag proteolysis. Immunization of MHC IIKRKI/KI mice identified impairments in MHC II and MHC class I presentation of soluble, cell-associated and/or DC-targeted OVA via mAb specific for DC surface receptor Clec9A (anti-Clec9A-OVA mAb). Reduced T cell responses and impaired CTL killing was observed in MHC IIKRKI/KI mice following immunization with cell-associated and anti-Clec9AOVA. Immunization of MHC IIKRKI/KI mice failed to elicit follicular Th cell responses and generated barely detectable Ab to antiClec9A mAb-targeted Ag. In summary, MHC II ubiquitination in DCs impacts the homeostasis, phenotype, cytokine production, and Ag proteolysis by DCs with consequences for Ag presentation and T cell and Ab-mediated immunity.
AB - MHC class II (MHC II) Ag presentation by dendritic cells (DCs) is critical for CD4+ T cell immunity. Cell surface levels of MHC II loaded with peptide is controlled by ubiquitination. In this study, we have examined how MHC II ubiquitination impacts immunity using MHC IIKRKI/KI mice expressing mutant MHC II molecules that are unable to be ubiquitinated. Numbers of conventional DC (cDC) 1, cDC2 and plasmacytoid DCs were significantly reduced in MHC IIKRKI/KI spleen, with the remaining MHC IIKRKI/KI DCs expressing an altered surface phenotype. Whereas Ag uptake, endosomal pH, and cathepsin protease activity were unaltered, MHC IIKRKI/KI cDC1 produced increased inflammatory cytokines and possessed defects in Ag proteolysis. Immunization of MHC IIKRKI/KI mice identified impairments in MHC II and MHC class I presentation of soluble, cell-associated and/or DC-targeted OVA via mAb specific for DC surface receptor Clec9A (anti-Clec9A-OVA mAb). Reduced T cell responses and impaired CTL killing was observed in MHC IIKRKI/KI mice following immunization with cell-associated and anti-Clec9AOVA. Immunization of MHC IIKRKI/KI mice failed to elicit follicular Th cell responses and generated barely detectable Ab to antiClec9A mAb-targeted Ag. In summary, MHC II ubiquitination in DCs impacts the homeostasis, phenotype, cytokine production, and Ag proteolysis by DCs with consequences for Ag presentation and T cell and Ab-mediated immunity.
UR - http://www.scopus.com/inward/record.url?scp=85118482334&partnerID=8YFLogxK
U2 - 10.4049/jimmunol.2001426
DO - 10.4049/jimmunol.2001426
M3 - Article
C2 - 34599081
AN - SCOPUS:85118482334
SN - 0022-1767
VL - 207
SP - 2255
EP - 2264
JO - Journal of Immunology
JF - Journal of Immunology
IS - 9
ER -